Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Oct 2019 Planned number of patients changed from 37 to 74.
- 27 Nov 2017 Status changed from not yet recruiting to recruiting.
- 05 Oct 2017 New trial record